Stay Ahead of the Competition - Free Exclusive Small Cap Reports Straight to Your Inbox

Avalon GloboCare Corp.

Published on:

Covid has brought the Biotech sector to the forefront… There’s no argument, the space hasn’t been remarkably successful in the last few years, but as of late, the biotech arena is outperforming the broader market, with analysts hypothesizing that it may be one of the frontrunning industry performers of 2023. (1)

In fact, some analysts predict the global biotech market sales to quadruple in the next ten years. (2)

The biotech industry’s worth is estimated to reach $2.44 Trillion by 2023’s year end, a CAGR of 15.83% “The factors driving the market include favorable government policies, the launch of new and advanced products, robust investment in the biotechnology sector, and rising demand for synthetic biology.”(3) 

Aging, disease, and the call for treatment have yet to be eradicated … the result? A more recession-proof vertical than many others, biotech stocks focused on treatment and innovation are entering the market undetected – and showing no limit. 

Our team has been on the hunt for the next potential breakout biotech stock, and we are putting this company at the top of our watchlist.

Introducing: Avalon GlobalCare (NASDAQ:ALBT) 

Website: Avalon Globocare (

The company describes itself as a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon GlobalCare (NASDAQ:ALBT) also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development. Additionally, ALBT performs competitively in the healthcare and CellTech industry markets. As described by the company, “Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.”(4)

Could this stock prove to be one of the biggest WINNERS of 2023 with huge upside potential?

NASDAQ:ALBT is a CellTech bio-developer with innovative and transformative immune effector cell therapy, exosome technology, and other cell-therapy-related companion diagnostics.

“Cell-based therapeutics are an emerging modality with the potential to treat many currently intractable diseases through uniquely powerful modes of action” as described by the National Center for Biotechnology Information (NIH).(5)
This company is making huge waves in the Cell based technology space with their recent new: 

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

An announcement of their breakthrough fusion gene map technology for the dof companion diagnostic kits and devices to improve personalized clinical management of leukemia patients is one of just many exciting developments on ALBT’s docket.

ALBT collaborated with the Lu Daopei Institute of Hematology to create  a fusion gene map database from over 1,000 patients with leukemia.

Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.(6)

This news is turning heads.

Fusion genes has led to the development of many successful anti-cancer drugs and will translate to more targeted therapy opportunities in the future.

ALBT has the potential to make massive strides in the anti-cancer drug space, so this is a huge development to keep your eyes on.

Based on the company’s structure, the integration of research and development to bioproduction has rapidly given ALBT a respected name in the cellular immunotherapy, exosome technology, and regenerative therapeutics space. ALBT is poised to make significant progress in advancing its scientific and clinical programs, particularly those focused on immuno-oncology and cellular medicines. 

Despite being a smallcap within the sector, the company is still cultivating impressive partnerships to help advance innovation. The company is working with the University of Pittsburgh Medical Center (UPMC) to develop new cancer immunotherapy approaches and streamline manufacturing processes. Additionally, ALBT has cultivated a  Research partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria with a goal is to co-develop a novel, cell-free, in-silico system that would expand ALBT’s ability to design and produce novel cell membrane proteins, including receptors found on the surface of immune and cancer cells that function in cell signaling.

Let’s look at the indicators:

ALBT – Upside of 126%, a Small Trading Float, and BULLISH Ratings

Despite the bullish sentiment, there are many factors working together to suggest that this opportunity could be ready to take off, and the price may give a well researched trader the opportunity to get in at the ground level.

The ticker has a 52-week high of $9.40, over double current levels. If the stock returns to this price, in fact, it would be upside of 126%. The company holds a trading float of just over $13.M, which is low for a NASDAQ stock. 

This potential sleeping giant is still relatively undiscovered, and sudden demand could potentially create a huge upswing in price.

When Wall Street learns about NASDAQ ALBT ‘s recent developments, this ticker could be ready to take off in a big way.

ALBT’s subsidiary and joint venture structure contribute to investor flexibility and R&D focus, enabling them to establish their leading role in the fields of immune effector cell therapy =, exosome-based regenerative therapeutics (their ACTEXTM platform), as well as “liquid biopsy” diagnostics.

The company achieves and fosters seamless integration of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.

The biotech industry is poised to soar this year, and this hidden gem as massive upside potential, at a discount price. Healthcare demands are ever growing, and demand for new medical treatments continues to grow. 

This biotech stock could have the biggest potential in the space right now. Add NASDAQ: ABLT to the top of your watchlist today.

As always, perform your due diligence before making any investment decision.

1. Here’s What to Expect From Biotech in 2023 – RealMoney (
2. Biotech is riding a wave of growth in funding. What’s next? | McKinsey

3. (Biotechnology Market Size Worth $2.44 Trillion By 2028 | CAGR 15.83% (

4.   Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules (

5. Engineering the next generation of cell-based therapeutics – PubMed (
6.  (Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center – PubMed (


Advertise With Us

Adamas One Corp.


Leave a Reply

Please enter your comment!
Please enter your name here